Hemogenyx Pharmaceuticals (LON:HEMO) Issues Quarterly Earnings Results

Hemogenyx Pharmaceuticals (LON:HEMO) issued its earnings results on Monday. The company reported GBX (181.10) (($2.41)) EPS for the quarter, Digital Look Earnings reports.

Hemogenyx Pharmaceuticals Stock Down 1.1 %

Shares of HEMO opened at GBX 183 ($2.43) on Monday. Hemogenyx Pharmaceuticals has a 52-week low of GBX 160 ($2.13) and a 52-week high of GBX 1,200 ($15.96). The company has a quick ratio of 6.72, a current ratio of 4.38 and a debt-to-equity ratio of 90.87. The stock has a fifty day simple moving average of GBX 217.95 and a two-hundred day simple moving average of GBX 200.16. The company has a market capitalization of £6.52 million, a PE ratio of -936.14 and a beta of 3.14.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.